Business & Finance
Moberg Pharma swings to profit in Q1 2018
9 May 2018 -

Moberg Pharma AB (STO:MOB), a researcher and producer of topical treatments for skin conditions, reported on Tuesday that its net profit after tax was SEK2.0m, or diluted EPS of SEK0.12, for the first quarter of 2018, from January 2018 to March 2018.

This was an improvement over a net loss of SEK3.0m, or SEK0.17 loss per diluted share, in the first quarter 2017.

Net revenues for the quarter were SEK91.5m, as compared with SEK104.6m in the first quarter last year.